|1.78 -0.04 (-2.2%)||12-05 16:00|
|Targets||6-month :||2.46||1-year :||3.07|
|Resists||First :||2.11||Second :||2.63|
|Supports||First :||1.26||Second :||1.05|
|MAs||MA(5) :||1.8||MA(20) :||1.77|
|MA(100) :||2.09||MA(250) :||1.5|
|MACD||MACD :||-0.2||Signal :||-0.2|
|%K %D||K(14,3) :||50.3||D(3) :||49.3|
|52-week||High :||3.89||Low :||0.5|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TSHA ] has closed below upper band by 43.3%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||1.85 - 1.86||1.86 - 1.87|
|Low:||1.71 - 1.73||1.73 - 1.74|
|Close:||1.76 - 1.78||1.78 - 1.8|
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||187 (M)|
|Shares Float||85 (M)|
|Held by Insiders||39.3 (%)|
|Held by Institutions||28.6 (%)|
|Shares Short||13,950 (K)|
|Shares Short P.Month||10,020 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.26|
|Profit Margin||0 %|
|Operating Margin||-329.5 %|
|Return on Assets (ttm)||-28.2 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0.01|
|Sales Per Share||0.07|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-42 (M)|
|Levered Free Cash Flow||102 (M)|
|Price to Book value||-6.85|
|Price to Sales||23.19|
|Price to Cash Flow||-7.89|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|